Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.

scientific article

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2147/OTT.S62639
P932PMC publication ID4043805
P698PubMed publication ID24920920
P5875ResearchGate publication ID263056948

P50authorKang-Yi SuQ56989064
Wei-Yu LiaoQ57020031
Chong-Jen YuQ42255080
P2093author name stringHsuan-Yu Chen
Gee-Chen Chang
Sung-Liang Yu
Tsung-Ying Yang
Jeng-Sen Tseng
Kun-Chieh Chen
Kuo-Hsuan Hsu
Chi-Ren Tsai
Jeremy Jw Chen
Meen-Hsin Tsai
P2860cites workPredictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.Q53561291
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Q27852408
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaQ27860881
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRQ29547545
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialQ29619975
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerQ29620301
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyQ29620648
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.Q33402098
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.Q34328665
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancerQ35196345
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-lineQ36040619
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedQ36766720
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexedQ36821156
Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancerQ37609860
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.Q37659062
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Q37760357
Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testingQ37994383
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?Q38080824
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancerQ43292962
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.Q44845388
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialQ44886865
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutationsQ45155265
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.Q45964243
Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugsQ46144064
Retrospective study of erlotinib in patients with advanced squamous lung cancerQ48713500
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectadenocarcinomaQ356033
P304page(s)799-805
P577publication date2014-05-23
P1433published inOncoTargets and TherapyQ7092081
P1476titlePrior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
P478volume7

Reverse relations

cites work (P2860)
Q38676692Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).
Q36413062Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Q52562714Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review.
Q41728235Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
Q38486882Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.
Q26741318Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
Q28075291Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options

Search more.